Breast Cancer
New findings from the United Kingdom and United States in the area of breast cancer detailed
Published in Women's Health Weekly, September 21st, 2006
Study 1: Estrogen receptor-positive breast cancers respond to therapy combining docetaxel and gefitinib.
"We have evaluated the activity and safety of gefitinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in combination with docetaxel as first-line treatment of women with metastatic breast cancer (MBC). In total, 41 patients with MBC were enrolled in a first-line combination therapy study with oral gefitinib (250 mg day-1) and intravenous docetaxel (75 mg.m-2, the first 14 patients; or 100...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
Combined estrogen and testosterone therapy increases risk of breast cancer in women - Breast Cancer
Exemestane after tamoxifen therapy may be associated with positive body composition changes - Menopause
Hot flash-induced sleep disturbances are reduced during rapid eye movement sleep - Sexual & Reproductive Health
Estrogen therapy may decrease loss of gray matter volume in postmenopausal women - Age-Related Macular Degeneration
Neovascular age-related macular degeneration risk is reduced by hormone therapy - Alcohol Use
Study refutes theory that alcohol use is lower in European countries than in U.S. - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
